Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
New Insights into Diagnosis and Treatment of Prostate Cancer and...
share announcement

New Insights into Diagnosis and Treatment of Prostate Cancer and Urological Epidemiology

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".

Deadline for manuscript submissions: closed (31 August 2021) | Viewed by 6805

Special Issue Editors

Prof. Piotr Chlosta

E-Mail Website
Guest Editor
Medical College, Jagiellonian University, Krakow, Poland
Interests: prostate cancer; bladder cancer; kidney cancer; urologic surgery; laparoscopy; endourology
Dr. Mikolaj Przydacz

E-Mail Website
Co-Guest Editor
Medical College, Jagiellonian University, Krakow, Poland
Interests: functional urology; neurourology; overacitive bladder; urinary incontinence

Special Issue Information

Dear Colleagues,

Prostate cancer is the second most commonly diagnosed cancer in men. Patients with localized prostate cancer mostly undergo definitive curative therapy with surgery or radiation, followed by monitoring of prostate-specific antigen (PSA). However, approximately 30% of patients who undergo definitive treatment will have disease relapse. Androgen-deprivation therapy has been the mainstay of treatment for advanced prostate cancer and usually induces disease regression commonly defined by PSA declines, radiographic responses, and clinical improvement. Unfortunately, many of these patients will continue to experience PSA rise or biochemical recurrence. Over time, castration-resistant prostate cancer (CRPC) cells emerge. CRPC is a heterogeneous disease state that ranges from the serologic progression of disease-only with no radiographic or clinical evidence of metastasis to evidence of metastasis and significant debilitating symptoms from disease progression. Therefore, there is an unmet need to identify new reliable markers, new non-invasive diagnostic approaches, new therapeutic targets, and novel drugs with appropriate treatment therapies to delay and/or overcome the development of CRPC, which results in cancer metastasis.

Apart from urological oncology, non-malignant urological conditions are highly prevalent but not often highly prioritized for investigation in the context of multiple chronic conditions, particularly due to a perception of a lack of rigorous, quality outcome studies. Although these conditions frequently affect patient quality of life, their effect on other patient outcomes has been less well characterized. Symptoms commonly attributed to non-malignant urologic conditions can often be caused by other conditions and, therefore, standard diagnostic codes have poor accuracy for capturing benign urologic disease burden compared to other medical specialties. This underscores the importance of developing new sources and methods of inquiry in this area.

In light of these new advancements and needs, the Journal of Clinical Medicine has launched a Special Issue on advancements in the diagnosis and treatment of prostate cancer and urological epidemiology. We are prioritizing high-quality original studies, but also welcome well-designed meta-analyses and well reviews. We look forward to your contribution.

Prof. Piotr Chlosta
Dr. Mikolaj Przydacz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Biomarkers
  • Genetics
  • Novel therapeutics
  • Targeted therapies
  • Focal therapy
  • Next-generation imaging 
  • Immunotherapy
  • Epidemiology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 1302 KiB  
Article
The Role of Prostate Combination Biopsy Consisting of Targeted and Additional Systematic Biopsy
by Chung Un Lee, Joongwon Choi, Si Hyun Sung, Jae Hoon Chung, Wan Song, Minyong Kang, Hyun Hwan Sung, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee and Hwang Gyun Jeon
J. Clin. Med. 2021, 10(21), 4804; https://doi.org/10.3390/jcm10214804 - 20 Oct 2021
Viewed by 1495
Abstract
Background: To identify the role of combination biopsy, which consists of both targeted and additional systematic cores, in the diagnosis of clinically significant prostate cancer (csPCa). Methods: We retrospectively reviewed patients with PSA levels 2.5–15 ng/mL who have a suspicious prostate lesion (with [...] Read more.
Background: To identify the role of combination biopsy, which consists of both targeted and additional systematic cores, in the diagnosis of clinically significant prostate cancer (csPCa). Methods: We retrospectively reviewed patients with PSA levels 2.5–15 ng/mL who have a suspicious prostate lesion (with the Prostate Imaging Reporting and Data System (PI-RADS) ≥ 3) on multiparametric MRI (mpMRI) between January 2016 and December 2018. We analyzed biopsy results by PI-RADS score and biopsy methods (systematic, targeted, and combination biopsy). Results: Of the 711 total patients, an average of 4.0 ± 1.8 targeted and 8.6 ± 3.1 additional systematic biopsies were performed. The additional systematic biopsies were sampled outside the targeted biopsy area. The combination biopsies detected more csPCa (201 patients, 28.3%) than did the targeted (175 patients, 24.6%) or systematic (124 patients, 17.4%) biopsies alone (p < 0.001). In the initial biopsy samples, there was a 7% increase in the detection of csPCa than in targeted biopsy (62% to 69%). It increased by 11% in repeat biopsy (46% to 57%). There was no statistical significance in both groups (p = 0.3174). Conclusions: Combination biopsy has the benefit of detecting csPCa in both initial and repeat biopsy when there is a suspicious lesion on mpMRI. Full article
(This article belongs to the Special Issue New Insights into Diagnosis and Treatment of Prostate Cancer and Urological Epidemiology)
►▼ Show Figures

Figure 1

7 pages, 212 KiB  
Article
All-Cause Mortality Risk in National Prostate Cancer Cohort: An Impact of Population-Based Prostate Cancer Screening
by Ausvydas Patasius and Giedre Smailyte
J. Clin. Med. 2021, 10(11), 2459; https://doi.org/10.3390/jcm10112459 - 1 Jun 2021
Cited by 2 | Viewed by 1814
Abstract
The aim of this study is to evaluate all-cause mortality risk differences before and during prostate cancer screening, with a profound focus on the differences between screened and not-screened patient groups. Prostate cancer cases diagnosed between 1998 and 2016 were identified from the [...] Read more.
The aim of this study is to evaluate all-cause mortality risk differences before and during prostate cancer screening, with a profound focus on the differences between screened and not-screened patient groups. Prostate cancer cases diagnosed between 1998 and 2016 were identified from the population-based Lithuanian Cancer Registry and linked with screening status in the National Health Insurance Fund database. The analysis was stratified by a period of diagnosis and screening status. Standardized mortality ratios (SMRs) were used to assess all-cause and cause-specific mortality risk. The SMRs were calculated by dividing the observed number of deaths among prostate cancer patients by the expected number of deaths from the general population. All-cause SMR (1.45 (95% CI 1.42–1.48)) in the pre-screening period was higher compared to the screening period (SMR = 1.17 (95% CI 1.15–1.19)). An increased all-cause mortality risk among prostate cancer patients was observed in the not-screened patient population (SMR = 1.76 (95% CI 1.71–1.82)), while all-cause mortality risk in the screened patient population was similar to the general population (SMR = 1.00 (95% CI 0.97–1.02)). Screened patients with localized stage of disease had lower all-cause mortality risk than the general population (SMR = 0.72 (95% CI 0.70–0.75)). In conclusion, men with prostate cancer in Lithuania had excess all-cause mortality risk compared to the general population. The all-cause mortality risk among screened patients was not higher than expected. Full article
(This article belongs to the Special Issue New Insights into Diagnosis and Treatment of Prostate Cancer and Urological Epidemiology)
10 pages, 381 KiB  
Article
Population-Level Prevalence, Bother, and Treatment Behavior for Urinary Incontinence in an Eastern European Country: Findings from the LUTS POLAND Study
by Mikolaj Przydacz, Marcin Chlosta and Piotr Chlosta
J. Clin. Med. 2021, 10(11), 2314; https://doi.org/10.3390/jcm10112314 - 26 May 2021
Cited by 8 | Viewed by 2714
Abstract
Objectives: Population-level data are lacking for urinary incontinence (UI) in Central and Eastern European countries. Therefore, the objective of this study was to estimate the prevalence, bother, and behavior regarding treatment for UI in a population-representative group of Polish adults aged ≥ 40 [...] Read more.
Objectives: Population-level data are lacking for urinary incontinence (UI) in Central and Eastern European countries. Therefore, the objective of this study was to estimate the prevalence, bother, and behavior regarding treatment for UI in a population-representative group of Polish adults aged ≥ 40 years. Methods: Data for this epidemiological study were derived from the larger LUTS POLAND project, in which a group of adults that typified the Polish population were surveyed, by telephone, about lower urinary tract symptoms. Respondents were classified by age, sex, and place of residence. UI was assessed with a standard protocol and established International Continence Society definitions. Results: The LUTS POLAND survey included 6005 completed interviews. The prevalence of UI was 14.6–25.4%; women reported a greater occurrence compared with men (p < 0.001). For both sexes, UI prevalence increased with age. Stress UI was the most common type of UI in women, and urgency UI was the most prevalent in men. We did not find a difference in prevalence between urban and rural areas. Individuals were greatly bothered by UI. For women, mixed UI was the most bothersome, whereas for men, leak for no reason was most annoying. More than half of respondents (51.4–62.3%) who reported UI expressed anxiety about the effect of UI on their quality of life. Nevertheless, only around one third (29.2–38.1%) of respondents with UI sought treatment, most of whom received treatment. Persons from urban and rural areas did not differ in the degrees of treatment seeking and treatment receiving. Conclusion: Urinary incontinence was prevalent and greatly bothersome among Polish adults aged ≥ 40 years. Consequently, UI had detrimental effects on quality of life. Nonetheless, most affected persons did not seek treatment. Therefore, we need to increase population awareness in Poland about UI and available treatment methods, and we need to ensure adequate allocation of government and healthcare system resources. Full article
(This article belongs to the Special Issue New Insights into Diagnosis and Treatment of Prostate Cancer and Urological Epidemiology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop